Table 3.
First-line treatments.
| National population1)(n=811) | Regional population1)(n=127) | |
|---|---|---|
| Surgery | ||
| n (%) | 460 (56.7%) | 83 (65.4%) |
| (95% CI for %) | (53.2-60.2) | (56.4-73.6) |
| Time to treatment (months), mean (median) | 0.8 (0.0) | 0.9 (0.0) |
| (95% CI for mean) | (0.6-1.0) | (0.4-1.4) |
| SSA2) | ||
| n (%) | 201 (24.8%) | 36 (28.3%) |
| (95% CI for %) | (21.8-27.9) | (20.7-37.0) |
| Time to treatment (months), mean (median) | 3.0 (1.7) | 2.1 (1.6) |
| (95% CI for mean) | (2.2-3.8) | (1.5-2.7) |
| IFN-alpha | ||
| n (%) | 10 (1.2%) | n<5 |
| (95% CI for %) | (0.6-2.3) | |
| Time to treatment (months), mean (median) | 2.1 (2.4) | n<5 |
| (95% CI for mean) | (1.3-2.9) | |
| Chemotherapy | ||
| n (%) | 31 (3.8%) | n<5 |
| (95% CI for %) | (2.6-5.4) | |
| Time to treatment (months), mean (median) | 4.3 (2.3) | n<5 |
| (95% CI for mean) | (2.0-6.5) |
CI: confidence interval; IFN: interferon; SSA: somatostatin analogues.
Footnotes:
1) The Regional population is a subgroup of the National population; hence, the National population and the Regional population should not be compared.
2) Perioperative use of SSA may not have been captured to a full extent, if this was administered by health care personnel (and not purchased by the patient via a prescription).